

Choroid and Enhanced Depth Imaging Optical Coherence Tomography

Raşit Kılıç*

¹Department of Ophthalmology, Faculty of Medicine, Ahi Evran University, Turkey

***Corresponding author:** Raşit Kılıç, Bağbaşı, Sahir Kurutluoğlu Cad. No:100, 40100 Kırşehir, Turkey, Tel: +905055030927; Fax: +903862803917; Email: kilicrasit@gmail.com

Copyright: © 2017 Raşit Kılıç. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.

Original Submission

Received: December 22, 2016

Accepted: January 13, 2017

Published: January 20, 2017

Open Peer Review Status: Editorials, news items, analysis articles, and features do not undergo external peer review.

How to cite this article: Raşit Kılıç. Choroid and Enhanced Depth Imaging Optical Coherence Tomography. Curr Updates Ophthalmol. (2017) 1: 2.1

Current Updates in Ophthalmology

Choroid has a common vascular meshwork and therefore a vital importance for the blood supply of the outer retina and the retinal pigment epithelium. It is the only source for the photoreceptor cells in the avascular fovea that have high metabolic and oxygen exchange needs [1]. Choroidal blood flow changes can therefore unfavorably affect the fovea and visual acuity. Many disorders such as angioid streaks, central serous chorioretinopathy, age-related macular degeneration, polypoidal choroidal vasculopathy and degenerative myopia originate from the choroid. In addition, a lot of systemic diseases can affect choroidal structure by influencing hemodynamics. On the other part, the choroid could be a potential target for some inflammatory disorders such as Behçet's disease, Vogt-Koyanagi-Harada and sarcoidosis. Based on this information, understanding of choroidal physiopathology is essential for preventing chorioretinal disorders.

Optical coherence tomography is a non-invasive method that can provide sectional images from the eye structures such as cornea and retina. It has therefore become a significant device in the ophthalmology clinics. The recently developed enhanced depth imaging optical coherence tomography (EDI-OCT) has enabled more detailed assessment of the choroid [2]. The choroid could be imaged in a limited manner formerly but it has been possible to attain micrometer-level in vivo choroidal images with EDI-OCT. It can facilitate understanding the physiopathology of ophthalmic disorders such as age-related macular degeneration, degenerative myopia, polypoidal choroidal vasculopathy and glaucoma as well as impacts of systemic diseases such as hypertension and diabetes mellitus on choroid.

Normal choroidal thickness was evaluated in many studies for establishing normal data. It was shown that increasing age, axial length and myopia were significant factors influencing on choroidal thickness [3,4]. An increasing number of studies have also focused on identifying the relationship between choroidal thickness and many ophthalmic and systemic disorders. Choroidal thickness was found to be decreased in age related macular degeneration, whereas it was found to be increased in polypoidal choroidal vasculopathy [5,6]. Choroidal thickness was also evaluated after anti-VEGF treatment in these disorders [7]. Thickened choroid was observed in central serous chorioretinopathy in comparison with healthy eyes [8]. High myopia was correlated with reduced choroidal thickness [9]. On the other hand, increased choroidal thickness associated with inflammation was found in acute phase of Vogt-Koyanagi-Harada, sarcoidosis and Behçet's uveitis [10-12]. While a statistically significantly thicker choroidal thickness was found in many systemic immune-mediated inflammatory disorders such as ankylosing spondylitis and psoriasis, not found in others [13-15]. Vascular structures are affected by systemic diseases such as hypertension and diabetes mellitus and choroidal thickness was found to be decreased in patients with the diseases [16,17]. Consequently, it was shown using EDI-OCT that choroid could be affected by many systemic disorders. Moreover, it was also

shown that significant choroidal changes could occur in many sight-threatening ocular diseases.

There is a limitation evaluating choroidal thickness with EDI-OCT that is the difficulties determining the exact choroidal border in some cases. However, it is possible to obtain more detailed information from choroid using swept-source optical coherence tomography that has longer wavelength, higher penetration and lower scattering laser source [18]. Although all the improvements in choroid imaging, the choroidal physiopathology is still not completely understood. Further investigations are therefore needed for fully understanding choroidal physiopathology.

References

1. Mrejen S, Spaide RF. Optical coherence tomography: imaging of the choroid and beyond. *Surv Ophthalmol.* 2013; 58: 387-429.
2. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. *Am J Ophthalmol.* 2008; 146: 496-500.
3. Tuncer I, Karahan E, Zengin MO, Atalay E, Polat N. Choroidal thickness in relation to sex, age, refractive error, and axial length in healthy Turkish subjects. *Int Ophthalmol.* 2015; 35: 403-410.
4. Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. *Invest Ophthalmol Vis Sci.* 2010; 51: 2173-2176.
5. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. *Ophthalmology* 2011; 118: 840-845.
6. Rishi P, Rishi E, Mathur G, Raval V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normals. *Eye (Lond).* 2013; 27: 1038-1043.
7. Ting DS, Ng WY, Ng SR, Tan SP, Yeo IY, et al. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. *Am J Ophthalmol.* 2016; 164: 128-136.
8. Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. *Int Ophthalmol.* 2014; 34: 7-13.
9. Ho M, Liu DT, Chan VC, Lam DS. Choroidal thickness measurement in myopic eyes by enhanced depth optical coherence tomography. *Ophthalmology.* 2013; 120: 1909-1914.
10. Fong AH, Li KK, Wong D. Choroidal evaluation using

Current Updates in Ophthalmology

enhanced depth imaging spectral-domain optical coherence tomography in Vogt-Koyanagi-Harada disease. *Retina*. 2011; 31: 502-509.

11. Ishikawa S, Taguchi M, Muraoka T, Sakurai Y, Kanda T, et al. Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behcet's disease. *Br J Ophthalmol*. 2014;98:1508-1513.
12. Güngör SG, Akkoyun I, Reyhan NH, Yeşilirmak N, Yılmaz G. Choroidal thickness in ocular sarcoidosis during quiescent phase using enhanced depth imaging optical coherence tomography. *Ocul Immunol Inflamm*. 2014; 22: 287-293.
13. Kola M, Kalkisim A, Karkucak M, Turk A, Capkin E, Can I, et al. Evaluation of choroidal thickness in ankylosing spondylitis using optical coherence tomography. *Ocul Immunol Inflamm* 2014;22:434-438.
14. Onal IK, Yuksel E, Bayrakceken K, Demir MM, Karaca EE, et al. Measurement and clinical implications of choroidal thickness in patients with inflammatory bowel disease. *Arq Bras Ophthalmol* 2015;78:278-282.
15. Kılıç R, Kurt A, Acer E, Oktem Ç, Kocamiş O. Choroidal thickness in psoriasis. *Int Ophthalmol*. 2016.
16. Unsal E, Eltutar K, Zirtiloğlu S, Dinçer N, Özdoğan Erkul S, et al. Choroidal thickness in patients with diabetic retinopathy. *Clin Ophthalmol*. 2014; 8: 637-642.
17. Akay F, Gundogan FC, Yolcu U, Toyran S, Uzun S. Choroidal thickness in systemic arterial hypertension. *Eur J Ophthalmol*. 2016; 26: 152-157.
18. Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, et al. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2011; 52: 4971-4978.